Overall, these complementary but distinct approaches to study the biology of APP, Aβ, and BACE-1 in FXS and to rescue disease phenotypes in response to compound 9 could provide solid preclinical data to support testing BACE-1 inhibitors in FXS clinical trials. The gene discussed is APP; the disease is fragile X syndrome.